Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients

Background:PPM1D (WIP1) negatively regulates by dephosphorylation many proteins including p53 tumour suppressor. The truncating mutations (nonsense and frameshift) in exon 6 of PPM1D were found recently in blood cells of patients with breast, ovarian or colorectal cancer. These mutants code for gain-of-function PPM1D with retained phosphatase activity. Their significance in carcinogenesis is unknown.Methods:The exon 6 of PPM1D was sequenced in blood DNA of 543 non-small-cell lung cancer patients (NSCLC). The functional significance of selected PPM1D alterations (Arg458X, Lys469Glu) was compared with the wild-type gene and examined by recombinant DNA techniques, immunoblotting and luciferase reporter assays.Results:The frameshift mutations were found in five NSCLC patients (5/543; 0.92%), all of them had squamous cell carcinomas (5/328; 1.5%). All patients with the mutations were exposed, before the blood collection, to the DNA damaging agents as a part of chemotherapeutic regimen. Functional tests demonstrated that truncating mutation Arg458X causes enhancement of dephosphorylation activity of PPM1D toward serine 15 of p53, whereas Lys469Glu version is equivalent to the wild-type. Neither version of PPM1D (wild-type, Arg458X, Lys469Glu) significantly modulated the ability of p53 to transactivate promoters of the examined p53-target genes (BAX and MDM2).Conclusions:The truncating mutations of PPM1D are present in blood DNA of NSCLC patients at frequency similar to percentage determined for ovarian cancer patients. Our findings raise a question if the detected lesions are a result of chemotherapy.

[1]  B. Vogelstein,et al.  Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.

[2]  Y Taya,et al.  Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. , 1998, Science.

[3]  Marie-Claude Marsolier-Kergoat,et al.  The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase , 2007, Oncogene.

[4]  R. McLendon,et al.  Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas , 2014, Nature Genetics.

[5]  A. Kristjuhan,et al.  p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin , 2001, Oncogene.

[6]  Wei Gu,et al.  Modes of p53 Regulation , 2009, Cell.

[7]  D. Butkiewicz,et al.  Nutlin-3a, an MDM2 antagonist and p53 activator, helps to preserve the replicative potential of cancer cells treated with a genotoxic dose of resveratrol , 2013, Molecular Biology Reports.

[8]  David M. Thomas,et al.  Li-Fraumeni syndrome: cancer risk assessment and clinical management , 2014, Nature Reviews Clinical Oncology.

[9]  L. Donehower,et al.  The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. , 2004, Molecular cell.

[10]  K. Scheidtmann,et al.  p53 phosphorylation mutants retain transcription activity. , 1995, Oncogene.

[11]  M. Oren,et al.  A functional p53-responsive intronic promoter is contained within the human mdm2 gene. , 1995, Nucleic acids research.

[12]  L. Donehower,et al.  PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. , 2005, Genes & development.

[13]  J. Bartek,et al.  Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint , 2013, The Journal of cell biology.

[14]  J. Allan,et al.  Mechanisms of therapy-related carcinogenesis , 2005, Nature Reviews Cancer.

[15]  Y. Shiloh.  ATM and related protein kinases: safeguarding genome integrity , 2003, Nature Reviews Cancer.

[16]  Peter Donnelly,et al.  Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer , 2012, Nature.

[17]  E. Appella,et al.  Wip1 phosphatase modulates ATM-dependent signaling pathways. , 2006, Molecular cell.

[18]  Harvey Risch,et al.  PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. , 2014, Journal of the National Cancer Institute.

[19]  Y Taya,et al.  Enhanced phosphorylation of p53 by ATM in response to DNA damage. , 1998, Science.

[20]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[21]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.